Zobrazeno 1 - 10
of 216
pro vyhledávání: ''
Publikováno v:
Acta Oncologica. 60:1100-1105
Background With the first- and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), clinical benefit and rash correlate together. EGFR TKI-induced rash can be alleviated with topical corticosteroids and tetracy
Publikováno v:
Drug Design, Development and Therapy
Neovascular age-related macular degeneration (nAMD) treatment has been revolutionized by the introduction of vascular endothelial growth factor antagonists (anti-VEGF), but the need for frequent intravitreal injections poses a heavy burden to patient
Autor:
Matteo Renzulli, Antonella Forgione, Francesca Benevento, Francesco Tovoli, Alessandro Granito, Fabio Piscaglia, Sara Marinelli
Publikováno v:
Journal of Hepatocellular Carcinoma
Regorafenib was the first drug to demonstrate a survival benefit as a second-line agent after sorafenib failure in patients with unresectable hepatocellular carcinoma (HCC). Recent studies have shown that its mechanism of action is not only limited t
Publikováno v:
Expert Review of Hematology. 14:365-376
Introduction: Impressive therapeutic progress is being made in the management of multiple myeloma (MM). his progress is related to the introduction of several new classes of therapeutic agents incl...
Autor:
Sujin Choi, Hee Young Shin, Kyung Taek Hong, Bo Kyung Kim, Hyoung Jin Kang, Jung Yoon Choi, Hong Yul Ahn, Jung Eun Cheon
Publikováno v:
Pediatric Hematology and Oncology. 38:378-384
Imatinib is a BCR-ABL tyrosine kinase inhibitor used for the treatment of a variety of diseases including Philadelphia chromosome positive (Ph+) leukemia. We report a 15 year old male patient presenting with symptomatic acute intracerebral hemorrhage
Autor:
Theoklis E. Zaoutis, Danielle M. Zerr, Rangaraj Selvarangan, Neena Kanwar, Christopher J. Harrison, Jason G. Newland, Dithi Banerjee, Xuan Qin
Publikováno v:
Journal of Chemotherapy. 33:288-293
Ceftolozane/tazobactam (C/T), a cephalosporin/beta-lactamase inhibitor combination, was evaluated in vitro vs. 10 comparators against 299 pediatric extended-spectrum-cephalosporin-resistant or carbapenem-resistant (ESC-R/CR) Gram-negative Enterobacte
Publikováno v:
Expert Review of Clinical Pharmacology. 14:445-456
Introduction: Nilotinib is a second-generation tyrosine kinase inhibitor (TKI) targeting BCR/ABL, which is used for the first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients and the second-line treatment of most CML patients
Publikováno v:
Cancer Investigation. 39:235-239
Comprehensive molecular testing of individual tumors has led to the identification of novel molecularly defined cancer therapies and treatment indications. Given low frequencies of many molecular alterations, efficacy of therapies used to target them
Autor:
Yuka Ito, Koichiro Tsugawa, Marii Suehiro, Masaki Takahashi, Kiwako Ikegawa, Tsuneaki Tanaka, Takayuki Keira, Yasuyuki Kojima, Hiroko Minatogawa
Publikováno v:
Cancer Management and Research
Marii Suehiro,1,* Yasuyuki Kojima,2,* Masaki Takahashi,3,* Yuka Ito,4 Takayuki Keira,1 Kiwako Ikegawa,1 Hiroko Minatogawa,1 Koichiro Tsugawa,2 Tsuneaki Tanaka1 1Department of Pharmacy, St. Marianna University School of Medicine Hospital, Kawasaki-shi
Autor:
Eman Alshdaifat, Hashem Yaseen, Basil Obeidat, Amer Sindiani, Hasan Rawashdeh, Rawan A. Obeidat
Publikováno v:
International Journal of Women's Health
Amer Mahmoud Sindiani,1 Eman Alshdaifat,2 Basil Obeidat,1 Rawan Obeidat,1 Hasan Rawashdeh,1 Hashem Yaseen3 1Department of Obstetrics and Gynecology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan; 2Department of Obste